Greek Mountain Tea (Sideritis scardica Griseb.)
1. Identity, Botanical Classification, and Common Forms
Taxonomy and Nomenclature
Sideritis scardica is a species of flowering plant in the family Lamiaceae, commonly known as Greek mountain tea. It is native to Albania, Bulgaria, Greece (particularly in the area of Mount Olympus), Kosovo, and North Macedonia. It was first formally described in 1844.
The genus Sideritis — ironwort — includes several species native to the mountainous areas of Greece and the southern Balkan Peninsula, whose flowering herb is traded as "Greek mountain tea." The most common varieties are Sideritis scardica, Sideritis raeseri, Sideritis clandestina, and Sideritis syriaca (Malotiras). The genus is represented by 16 taxa in Greece, five of which are geographically endemic to certain mountainous regions of the country.
Greek mountain tea is also known as Ironwort, Shepherd's Tea, Tea of the Titans, Tea of the Gods, and Tsai Tou Vou Nou. Sideritis comes from the Greek word sideros, meaning iron or "he who is of iron." In Ancient Greece, plants associated with sideritis/iron were usually in reference to plants that heal wounds caused by iron weapons in battle.
The EU regulatory authority, the European Medicines Agency (EMA), issued a formal herbal monograph for this group of species. The Committee on Herbal Medicinal Products (HMPC) published the European Union Herbal Monograph covering Sideritis scardica Griseb., Sideritis clandestina (Bory & Chaub.) Hayek, and Sideritis raeseri Boiss. & Heldr., Herba, in Brussels, Belgium in 2015 (reference EMA/HMPC/39453/2015).
Morphology
Mountain tea is a perennial herbaceous plant with a well-developed root system; the stem is 15–40 cm and woody at the base, the leaves are opposite with gray hairs, the flowers are clustered in a dense spike, the middle bracts are 12–20 mm long (longer than the flowers), the corolla is lemon yellow with glandules, and the calyx is tubular-campanulate. During its flowering period from June to August, Greek mountain tea produces pale yellow, lip-shaped flowers grouped together in long spikes. The inflorescences emit a lemony fragrance and serve as a rich source of nectar for many beneficial insects.
Habitat and Ecology
Sideritis grows in the wild at elevations of 1,000 meters (approximately 3,281 feet) in the mountainous regions of Greece and other parts of the Mediterranean. Cultivation at low altitudes and in large monocultures has a negative influence on the concentration of the valuable ingredients and makes them less suitable for use as medicinal plants. It is worth noting that Sideritis is among the endangered species.
Common Forms and Preparations
Usually, Sideritis plants are applied in traditional medicine, mostly as an aromatic herbal tea. The tea is made from the aerial parts of the plant by infusion or decoction. Characterized by its woolly leaves and delicate small yellow flowers, the tea is traditionally made by brewing the dried flowers, stems, and leaves together. Beyond the loose dried herb, Sideritis scardica is also commercially available as standardized hydroalcoholic extracts in capsule form, which have been used in several published clinical trials. Sideritis has also been used in the form of an ethanol extract topically on the skin, as well as an antiseptic solution after tooth extraction.
Current metabolomic approaches demonstrate that the phytochemical composition of Sideritis varies among the taxa and depends on the genotype (thus explaining differences even among the same taxon), the environmental conditions, the time of collection, the plant part, and the extraction process.
2. Traditional and Historical Use
Ancient Greek and Classical Antiquity
The medicinal use of Greek mountain tea was described by the Greek physician Dioscorides, in De Materia Medica in 77 C.E. The genus name Sideritis is based on the Greek sideros (= iron) and refers to plants mentioned by Pliny in several places as remedies for wounds caused by iron weapons.
Balkan and Eastern Mediterranean Folk Medicine
Greek mountain tea was traditionally used as an anti-inflammatory, anti-ulcerative, antimicrobial, antiseptic, vulnerary, antispasmodic, anticonvulsant, analgesic, and carminative preparation in common colds, rhinitis, sore throat, angina pectoris, bronchitis, bronchial asthma, lung emphysema, rheumatic disorders, anemia, chronic kidney disease, prostatic hyperplasia, herpes, wound healing, and clearing the body of poisons.
A broad range of traditional uses of S. scardica are known, including the treatment of bronchitis, asthma, sore throat, the prevention of anemia, and the use as a tonic or poultice. Sideritis scardica is traditionally consumed as mountain tea in the Balkans to strengthen the body and improve mood.
Depending on the area, it is commonly known as Greek mountain tea, Shepherd's tea, Ironwort, Mursalski tea, Pirinski tea, or Caj Mali. On the Island of Crete, Greek mountain tea is known as "Malotiras," a name derived from the Italian words "Male" (human disease/sickness) and "tirare" (to draw out — remove), because during the time when the Venetians occupied Crete, they considered Greek mountain tea a valuable panacea known for clearing colds and respiratory infections.
Regulatory Recognition of Traditional Use
Greek mountain tea was adopted in 2015 in the European Union as a traditional herbal medicine, Herba Sideritis (Sideritis scardica Griseb.), for treating the common cold and mild gastrointestinal disorders; however, no registered or authorized well-established medicinal products in the EU/EEA Member States were identified (EMA/HMPC/39455/2015). There is no available monograph in National Pharmacopoeias or National Codexes currently used in the Member States, or any other monograph on Sideritis herba, beyond the EMA document.
According to the EMA Assessment Report on Sideritis scardica Griseb., 2016, mountain tea has been traditionally used to aid digestion, strengthen the immune system, and suppress the common cold and flu. The evidence of traditional medicinal use of Sideritis herba is confirmed by a large number of publications providing consistent information (EMA/HMPC/39454/2015).
3. Key Constituents and Active Compounds
Overview of the Phytochemical Profile
Chemical screening of Sideritis scardica Griseb. revealed that it contains a total of ninety-one phytoconstituents from ten chemical categories, including terpenoids, flavonoids, amino acids, phenylethanoid glycosides, phenolic acids, fatty acids, iridoids, sterols, nucleosides, and miscellaneous compounds.
According to phytochemical classification, terpenoids represent the biggest class of secondary metabolites, comprising about 24.18% of the total phytochemistry. Various research has reported their remarkable biological properties: anti-inflammatory, antitumor, analgesic, antimicrobial, antiviral, neuroprotective, antispasmodic, antihyperglycemic, antiplasmodial, cardioprotective, and immunomodulatory.
Flavonoids
These plants have been the subject of intensive phytochemical research and are characterized mainly by the presence of terpenes, flavonoids, phenylethanoid glucosides, phenolic acids, and essential oil. Chemical characterization of one studied 20% EtOH extract revealed a total phenolic content of 6.25%, with the major phenolic classes represented by flavonoids (1.2%), such as scutellarin, apigenin, luteolin, and their glycosides; phenolic acids, e.g., caffeoyl quinic acids (0.5%); and acteoside (0.4%).
Another main class of metabolites are phenolic compounds, such as flavones and their glycosides (7-O-glycosides of 8-hydroxyflavones; 7-O-glycosides of common flavones apigenin, luteolin, and chrysoeriol); coumarins; derivatives of caffeic, p-coumaric, chlorogenic, protocatechuic, and quinic acids; as well as phenylethanoid glycosides such as verbascoside, isoverbascoside, leucoseptoside A, martynoside, lavandulifolioside, forsythoside B, alyssonoside, and echinacoside.
Phenolic Acids
The traditional medicinal usage of the species is based on the phytochemical constituents, including phenolic acids (chlorogenic acid, 3-caffeoylquinic acid, feruloylquinic acid, and others), flavonoids and their derivatives (hypolaetin, isoscutellarein, and others), phenylethanoid glycosides (lavandulifolioside, verbascoside, echinacoside, allysonoside, and others), and terpenoids (mostly iridoid glycosides).
Terpenoids (Diterpenes)
It is well known that Mediterranean Sideritis spp. contain tetracyclic diterpenes of the ent-kaurane type. Numerous secondary metabolites with strong antioxidant capacity, such as phenolic acids, flavonoids, and kaurene diterpenes, have been isolated from different extracts of several Sideritis species.
Primary Active Constituents in Relation to Bioactivity
The primary active constituents of the caffeine-free Greek mountain tea appear to be phenolic acids, principally ferulic acid and chlorogenic acid, and the flavone compound apigenin, and it is likely the latter which underpins the small number of published psychophysiological effects of Greek mountain tea.
The plant is rich in polyphenols, such as flavonoids, hydroxycinnamic acid derivatives, and phenylethanoid glycosides. Pharmacological activities like antimicrobial, gastroprotective, and anti-inflammatory activity are mostly accredited to this class of secondary metabolites.
4. Mechanisms of Action
Antioxidant Activity
A review by Todorova and Trendafilova reported gastroprotective and anti-inflammatory effects in vitro alongside a correlation between antioxidant activity and the phenolic content of the tea extract. The plant exhibits antioxidant properties both due to the content of naturally occurring non-enzymatic antioxidants, as well as by increasing the activity of catalase in the liver.
Anti-Inflammatory Mechanisms
Due to the high concentration of phenolic compounds, S. scardica extracts exhibit dose-dependent anti-inflammatory and gastroprotective activities. Oral administration of investigated extracts caused a dose-dependent anti-inflammatory effect in a model of carrageenan-induced rat paw edema. Compared to the effect of the positive control, the anti-inflammatory drug indomethacin (4 mg/kg, which produced a 50% decrease in inflammation), diethyl ether and N-butanol extracts exhibited about the same effect in doses of 200 and 100 mg/kg (53.6% and 48.7%; 48.4% and 49.9%, respectively).
Gastroprotective Mechanisms
Research confirmed the gastroprotective activity of S. scardica extracts using a rat model of acute ethanol-induced gastric mucosa damage. The protective effect on the gastric mucosa was comparable to the antiulcer drug ranitidine.
Monoamine Reuptake Inhibition
Hydroalcoholic extracts were able to inhibit the reuptake of the monoamine neurotransmitters noradrenaline, dopamine, and serotonin in vitro (Feistel & Appel, 2013; Knörle, 2012). Extract from S. scardica also acts as a reuptake inhibitor of monoamine neurotransmitters — serotonin, noradrenaline, and dopamine — in vitro, which may result in a better mood when used by humans. This triple monoamine reuptake inhibition is a mechanism shared with some pharmaceutical antidepressants, though translation to confirmed clinical antidepressant effects in humans requires further controlled study.
Cerebral Blood Flow Modulation
The presence of polyphenols such as hydroxy-cinnamic acids and flavonoids in Sideritis scardica are likely responsible for the cognitive and mood effects of its consumption, and this could be underpinned by the ability of such polyphenols to prevent monoamine neurotransmitter reuptake and to increase cerebral blood flow (CBF).
Anti-Amyloid Mechanisms
Sideritis scardica extracts reduced amyloid-β aggregation and neurotoxicity in Alzheimer disease mouse models, in the nematode Caenorhabditis elegans, and in neuronal cell lines. The mid-polar extracts (40 and 50% ethanol) turned out to be the most active, decreasing the plaque number by 21% and delaying amyloid-β-induced paralysis by up to 3.5 hours. The more lipophilic extract fractions exhibited higher activity than the hydrophilic ones. Sideritis scardica extracts demonstrated pharmacological activity against characteristics of Alzheimer's disease in C. elegans, supporting current efforts to assess its potential for the treatment of cognitive decline. The active principle as well as the mode of action needs to be investigated in more detail.
5. Scientific Evidence by Area of Use
5.1 Respiratory Health (Common Cold, Cough, Bronchitis)
The respiratory applications of S. scardica rest primarily on traditional use evidence, which has been formally acknowledged by the EMA. As outlined in the monograph of the European Medicines Agency (EMA), the traditional use of Sideritis preparations (also known as mountain tea) is associated with the relief of mild gastrointestinal discomfort and coughs related to the common cold. In Balkan countries, Sideritis scardica Griseb. has been used mainly for treating lung diseases and cough of different origins (such as asthma and bronchitis).
S. scardica aerial parts are traditionally known for their anti-inflammatory, anti-microbial, anti-bacterial, anti-rheumatic, and gastroprotective properties. It is used as a loosening agent in bronchitis and bronchial asthma, against common cold and lung emphysema, as well.
Evidence strength: The EMA HMPC classification is based on traditional use. No large randomized controlled trials (RCTs) specifically addressing respiratory endpoints in humans have been identified in the literature reviewed. The indication rests on long-standing ethnobotanical practice corroborated by the plant's antimicrobial and anti-inflammatory activity in preclinical models.
5.2 Gastrointestinal Health
Modern evidence supports the traditional role of Greek mountain tea for respiratory, digestion, and inflammation. Gastroprotective activity of the extracts was investigated using an ethanol-induced acute stress ulcer in rats. The cytotoxic activity of plant extracts was assessed on PBMC, B16, and HL-60 cells and compared to the cytotoxicity of phenolic compounds identified in extracts. All investigated extracts produced dose-dependent gastroprotective activity with the efficacy comparable to that of the reference drug ranitidine.
Neither the tested extracts nor any phenolic compounds showed significant cytotoxic effect on human PBMC.
Evidence strength: Preclinical (animal model and in vitro) evidence is moderately robust, consistently supporting gastroprotection. Direct human clinical evidence for gastrointestinal endpoints is lacking from large RCTs; the EMA traditional-use designation covers this area.
5.3 Cognitive Function and Brain Health
This is the most extensively investigated area in clinical human research.
Wightman et al. (2018) — Key Double-Blind RCT: This randomized, double-blind, placebo-controlled, parallel groups trial enrolled N = 155 male and female participants aged 50–70 years, who were assessed for cognitive (N = 140), mood (N = 142), blood pressure (BP; N = 133), and cerebral blood flow (CBF; N = 57) effects of two doses of Greek mountain tea (475 mg and 950 mg) as well as an active control of 240 mg Ginkgo biloba and a placebo control, following acute consumption (Day 1) and following a month-long consumption period (Day 28). Relative to the placebo control, 950 mg Greek mountain tea produced significantly fewer false alarms on the Rapid Visual Information Processing (RVIP) task on Day 28 and significantly reduced state anxiety following 28 days' consumption (relative also to the active Ginkgo control).
Both doses of Greek mountain tea, relative to placebo, increased oxygenated haemoglobin (HbO) and oxygen saturation (Ox%) in the prefrontal cortex during completion of cognitively demanding tasks on Day 1. The higher dose also evinced greater levels of total (THb) and deoxygenated (Hb) haemoglobin on Day 1, but no additional effects were seen on CBF on Day 28 following either dose of Greek mountain tea.
The significantly improved cognitive performance following Greek mountain tea on Day 1 could be due to significant modulation of the CBF response. However, these improvements on Day 28 are more likely to be due to the reductions in state anxiety, suggesting that the former mechanism is more likely to facilitate acute cognitive effects and the latter more likely to underpin more prolonged cognitive improvements.
Behrendt et al. (2016) — Pilot Study: Behrendt et al. observed cognitive improvements in a sample of 64 healthy males and females (aged 25–60 years) following six-week supplementation of 330 mg/daily Sideritis scardica, including during stressful scenarios such as the presence of noise and incongruent stimuli.
Dimpfel et al. (2016) — Mild Cognitive Impairment: This extended to those experiencing mild cognitive impairment; Dimpfel et al. reported trending improvements on tasks of concentration, arithmetic calculation, and memory in 32 males and females aged 50–80 years following four-week supplementation of 380 mg/daily Sideritis scardica. However, both these trials co-supplemented Greek mountain tea with B vitamins and the latter also incorporated 120 mg Bacopa monnieri. This makes attributions to Sideritis alone complicated, as both B vitamins and Bacopa have the capacity to influence cognition and mood, including in the elderly.
Recent clinical studies aimed to assess the efficacy of several preparations of Sideritis scardica on the cognitive function of healthy individuals in a stressful environment and elderly adults with mild cognitive impairment and anxiety. S. scardica extracts were able to improve the mental performance of healthy subjects under stress conditions and of subjects suffering from mild cognitive impairment (MCI), which is a precursor of Alzheimer's disease.
Evidence strength: Moderate. The Wightman et al. (2018) study is the most methodologically rigorous single-ingredient trial to date. Positive signals have been observed for aspects of attention, picture recognition, state anxiety, and cerebral blood flow, particularly at the 950 mg dose over 28 days. Earlier trials were confounded by co-supplementation. The overall number of clinical trials remains small, and the field requires larger replication studies.
5.4 Neuroprotection and Alzheimer's Disease
Beyond its traditional uses in the Balkan area, Sideritis scardica is currently extensively investigated for its pharmacological activity in the central nervous system. Antidepressant, psychostimulating, cognition-enhancing, and neuroprotective properties have been described.
The therapeutic potential of S. scardica in neurodegenerative diseases, including Alzheimer's disease, has been previously explored. These studies have shown a positive impact on cognition and memory in AD-amyloidosis mouse models and aged C57Bl/6 mice using Sideritis euboea and S. scardica extracts.
The mid-polar extracts (40 and 50% ethanol) turned out to be the most active in C. elegans models, decreasing the plaque number by 21% and delaying amyloid-β-induced paralysis by up to 3.5 hours. Sideritis scardica extracts demonstrated pharmacological activity against characteristics of Alzheimer's disease also in C. elegans, supporting current efforts to assess its potential for the treatment of cognitive decline. The active principle as well as the mode of action needs to be investigated in more detail.
A published monograph on Herba Sideritis provides systematic information on the safety, efficacy, and quality of the herb, paving the way for its potential use in reducing the risk of age-related cognitive decline and neurodegenerative disorders. It includes details of botanical descriptions, chemical constituents, dosage recommendations, adverse effects, and interactions. Further preclinical and clinical research is crucial to fully validate the herb's health benefits and unravel the mechanisms underlying its adaptogenic effects.
Evidence strength: Preliminary. Evidence is currently concentrated in animal models (C. elegans, mouse models) and in vitro cell systems. No published human clinical trials specifically targeting Alzheimer's disease patients or prevention have been completed and reported.
5.5 Mood and Anxiety (Antidepressant/Anxiolytic Effects)
Sideritis scardica is currently extensively investigated for its pharmacological activity in the central nervous system. Antidepressant, psychostimulating, cognition-enhancing, and neuroprotective properties have been described. In the clinical trial by Wightman et al. (2018), both doses of Greek mountain tea attenuated a reduction in accuracy on the picture recognition task, and the 950 mg dose significantly reduced state anxiety following 28 days of consumption (relative also to the active Ginkgo control).
Sideritis scardica extracts, known for triple monoamine reuptake inhibition, have the potential for phytochemical therapy in treating mental disorders such as anxiety, depression, attention-deficit hyperactivity disorder, and neurodegenerative diseases. This claim, however, is based largely on in vitro mechanistic data and preliminary clinical observations; it is not established through Phase II/III clinical trials.
Evidence strength: Preliminary to moderate. The anxiolytic signal in the Wightman RCT is clinically observed in healthy older adults. The antidepressant mechanism (triple monoamine reuptake inhibition) is demonstrated in vitro. No large RCTs specifically enrolling patients with diagnosed depressive or anxiety disorders have been published.
5.6 Antimicrobial Activity
Previous studies on Sideritis extracts have documented a multitude of pharmacological activities, including antioxidant, anti-inflammatory, neuroprotective, anticholinesterase, and cytotoxic effects, in addition to antimicrobial properties. A variety of biological activities of Sideritis scardica have been reported: anti-inflammatory, gastroprotective, antiglioma, cytotoxic, antimicrobial, antioxidant, and others, including triple monoamine reuptake inhibition.
Evidence strength: Preclinical only (in vitro). No human clinical trials on antimicrobial endpoints have been identified.
5.7 Metabolic and Cardiovascular Effects
Regular consumption of mountain tea by rats has been shown to lead to weight loss and prevent insulin resistance by lowering blood glucose and triglyceride levels and increasing liver glycogen content. Many reports indicate a positive effect on digestive system, weight loss, and prevention of insulin resistance. Additionally, it exhibits antioxidant activity and anti-inflammatory effects.
Evidence strength: Preclinical (animal model) only for metabolic outcomes. Human clinical data in this domain are not available in the literature reviewed.
6. Body Systems Associated with Greek Mountain Tea
- Respiratory system: Traditional use for cough, common cold, bronchitis, asthma, and bronchial asthma; EMA traditional-use designation.
- Gastrointestinal system: Traditional and preclinical evidence for gastroprotection, anti-ulcer activity, and relief of mild GI discomfort; EMA traditional-use designation.
- Central nervous system: Growing preclinical and early clinical evidence for cognitive enhancement, anxiolytic activity, and neuroprotection, including preliminary Alzheimer's disease research.
- Cardiovascular/metabolic system: Preclinical evidence for blood glucose regulation, lipid modulation, and vasodilation; no published clinical data.
- Immune system: Traditional use as a tonic and immune-supportive preparation; corroborated by antimicrobial and anti-inflammatory in vitro data.
- Integumentary/wound system: Historical use as a wound-healing poultice and topical antiseptic; no modern controlled clinical evidence.
7. Dosage Forms and Dosages Reported in Studies
Dosages below are reported exactly as stated in peer-reviewed sources; they are not recommendations.
- Traditional herbal infusion: A single dose of 2–4 g of the comminuted aerial parts (roughly 1–2 heaped teaspoons of dried herb) in about 150–200 ml of freshly boiled water, steeped for around 5–10 minutes, then strained.
- Standardized extract — Behrendt et al. (2016): An herbal extract of Sideritis scardica (330 mg of an alcoholic aqueous extract) combined with B vitamins was studied in an open-labeled trial in 64 healthy 25–60-year-old participants taking the supplement orally twice daily for six weeks.
- Standardized extract — Dimpfel et al. (2016): Trending improvements were reported in 32 males and females aged 50–80 years following four-week supplementation of 380 mg/daily Sideritis scardica.
- Standardized extract — Wightman et al. (2018): Two doses — 475 mg and 950 mg of Greek mountain tea extract — were compared against an active control of 240 mg Ginkgo biloba and placebo, assessed acutely (Day 1) and after one month (Day 28) in 155 participants aged 50–70 years.
- Animal/preclinical reference dose: The dose of S. scardica extract (extraction solvent 20% ethanol, DER 5–9:1, containing 0.5–1.5% flavonoids and 0.1–0.4% caffeoylquinic acids) corresponded to a recommended human dose of 800–1200 mg.
8. Safety Considerations
Toxicology Studies
A study investigated the acute and repeated-dose oral toxicity of a S. scardica 20% (v/v) ethanol extract in Sprague Dawley rats, and mutagenicity using the Ames test. No gross pathological abnormalities and no toxicity signs or mortality were detected in animals treated with the dose of 2,000 mg/kg bw during 14 days of observation. The tested extract was assigned to category 5 of the GHS (Global Harmonized System), indicating very low acute toxicity.
To evaluate repeated-dose toxicity, an extract was tested over a 28-day period followed by a 14-day recovery period. No mortality and no changes in body/organ weight or food consumption were observed. The no-observed-adverse-effect-level (NOAEL) of the extract was determined at 1,000 mg/kg bw.
The results of Ames tests conducted on extracts of different polarity (water; 20% (v/v) ethanol; 50% (v/v) ethanol; n-heptane) were unequivocally negative. The study reveals no toxicity of S. scardica and no concerns for its mutagenic effects, supports its positive safety profile, and confirms the acknowledged traditional medicinal use in humans.
Adverse Reactions and Interactions per EMA Monograph
European herbal monographs indicate that, when prepared as a herbal tea and used at recommended doses for short periods, Sideritis herba has no specific pattern of reported adverse effects and no documented serious adverse reactions in the published literature at traditional doses.
No case of overdose has been reported. None are reported for adverse reactions; none are known for drug interactions.
Pregnancy, Lactation, and Pediatric Use
The monograph specifically notes that safety in pregnancy and lactation has not been established and advises against use in these periods due to a lack of data. No fertility data are available according to the EMA monograph.
Quality and Species Consistency
Cultivation at low altitudes and in large monocultures has a negative influence on the concentration of valuable ingredients. Not all mountain teas have the same concentration of essential oils and antioxidants, which are very important for their quality. The phytochemical variability across species, growing conditions, and extraction methods means that the generalizability of study findings from one extract to all commercial products should be approached with caution.
In Vitro Monoamine Reuptake Inhibition and Drug Interactions
Extract from S. scardica acts as a reuptake inhibitor of monoamine neurotransmitters — serotonin, noradrenaline, and dopamine — in vitro. Although no human drug interaction studies have been published to date in the sources reviewed, this in vitro pharmacological profile raises the theoretical concern of additive effects if combined with pharmaceutical serotonergic or noradrenergic drugs. This has not been confirmed in human clinical data.
References
- Wightman EL et al. "The Acute and Chronic Cognitive and Cerebral Blood Flow Effects of a Sideritis scardica (Greek Mountain Tea) Extract: A Double Blind, Randomized, Placebo Controlled, Parallel Groups Study in Healthy Humans." Nutrients 10(8):955, 2018. PMC6116054
- Wightman EL et al. Same study. PubMed entry 30042362.
- Heiner F et al. "Sideritis scardica extracts inhibit aggregation and toxicity of amyloid-β in Caenorhabditis elegans used as a model for Alzheimer's disease." PMC5933321
- Assessment of the Acute and Subchronic Toxicity and Mutagenicity of Sideritis scardica Griseb. Extracts. PMC6071134
- Polyphenols and Other Bioactive Compounds of Sideritis Plants and Their Potential Biological Activity. PMC7464829
- Sideritis scardica Extracts Demonstrate Neuroprotective Activity against Aβ25–35 Toxicity. PMC10142657
- An Innovative Approach to a Potential Neuroprotective Sideritis scardica-Clinoptilolite Phyto-Nanocarrier. PMC10855864
- Extracts of Sideritis scardica and Clinopodium vulgare Alleviate Cognitive Impairments in Scopolamine-Induced Rat Dementia. PMC10855470
- Traditionally Used Sideritis cypria Post.: Phytochemistry, Nutritional Content, Bioactive Compounds of Cultivated Populations. PMC7235332
- Chemical and Antimicrobial Evaluation of Supercritical and Conventional Sideritis scardica Griseb., Lamiaceae Extracts. PMC6268164
- A Comprehensive Phytochemical Analysis of Sideritis scardica Infusion Using Orbitrap UHPLC-HRMS. PMC10780595
- Genus Sideritis, section Empedoclia in southeastern Europe and Turkey – studies in ethnopharmacology and recent progress of biological activities. PMC6593022
- Beneficial Effects of Sideritis clandestina Extracts and Sideridiol against Amyloid β Toxicity. PMC10967505
- Panossian A. "Herba Sideritis: A putative adaptogen for reducing the risk of age-related cognitive decline and neurodegenerative disorders." Phytomedicine Plus, 2023. ScienceDirect
- Tadić VM et al. "Anti-inflammatory, gastroprotective, and cytotoxic effects of Sideritis scardica extracts." PubMed 22274814
- Todorova M and Trendafilova A. "Sideritis scardica Griseb., an endemic species of Balkan peninsula: Traditional uses, cultivation, chemical composition, biological activity." Journal of Ethnopharmacology, 2014. ScienceDirect
- Wikipedia. "Sideritis scardica."
- European Medicines Agency. "Sideritis herba – herbal medicinal product." EMA official page.
- European Medicines Agency HMPC. "Final European Union Herbal Monograph on Sideritis scardica Griseb.… herba." EMA/HMPC/39453/2015.
- Targeted Isolation of Coumarins From Sideritis Species Based on Antiviral Screening and Untargeted Metabolomics. PMC12212021
- Knörle R. "Extracts of Sideritis scardica as triple monoamine reuptake inhibitors." Journal of Neural Transmission 119:1477–1482, 2012. ResearchGate
Volver